Nano Scale Science-based Biomedical Research for Future Human Health and Happiness
Joon Hwang, Ph.D.
A. The Importance of Nanoscale Science-Based Biomedical Research for Future Human Health and Happiness
• (Importance of Nanoscale Science and Technology)
Nanoscale science and technology is beginning to present new possibilities and potential in the diagnosis and treatment of refractory diseases. The importance of research and development to establish more systematic and consistent diagnostic and treatment protocols for personalized diagnosis and treatment of patients with various intractable diseases and disorders is growing significantly.
• (Need for Development of Nanomedical Approaches)
Therefore, nanomedical approaches are expected to maximize the effectiveness of the 3Ps (precision, preventive, and personalized), the clinical targets of future nanomedicine, by generating new knowledge in screening for diseases and new drug candidates and studying the basic pharmacological mechanisms to treat intractable diseases and complex disorders.
• (Intractable diseases that must be addressed first)
Intractable diseases that must be addressed first through nano-scale-based nanomedicine convergence research include cancer, diabetes, geriatric diseases, cardiovascular diseases, ocular diseases, and specific target diseases closely related to genetics and metabolism. Diagnostic and treatment platform research, mechanism research, and medical clinical studies should be promoted.
• (Need to promote advancement and convergence of new biotechnology)
It is urgent to discover startups, foster star companies, and strengthen corporate capabilities and establish a comprehensive support system for new market entry of regional companies by promoting advancement and convergence of biotechnology and industries using digital transformation (DX) technologies such as big data, artificial intelligence, synchrotron radiation accelerators, and quantum computing.
• (Urgent need to establish a response strategy for the growth of the global market for functional biopharmaceutical materials)
Functional biomaterial technology, which determines the competitiveness of the biohealth industry, is at least 5 years behind major countries, but in order to preempt the market with a very high global market growth rate (USD 350 billion (KRW 420 trillion) in 2027 / CAGR 16%), the establishment and expansion of a functional biopharmaceutical material industry cluster through industry-academia cooperation is urgently required. Building an industrialization platform utilizing functional biomaterials satisfies the requirements necessary for the upcoming 4th Industrial Revolution and is a promising future food source that can grow together with the biohealth industry, a new national growth industry. • (Need to strengthen the role of the full-cycle technology support system through continuous research advancement) This research group has secured over 50 original technologies and intellectual property rights, and based on these, technology transfer to companies is increasing annually. Therefore, strengthening the role of the integrated support system, including strategies and space, equipment, technology, systems, experience, and networks, to support the full cycle of corporate growth is essential.
• (Leveraging the leading university's outstanding contribution and excellence in fostering the local bioindustry)
As the lead institution for this project, our research group is leading the way in key industries in Chungcheongbuk-do (biohealth and functional biomaterials). We are investing KRW 20 billion in research funds, including university-focused research institutes and leading research centers, to foster the future cutting-edge bioindustry based on core biomaterials technology R&D. In particular, by securing key priority projects from the Ministry of Trade, Industry and Energy and the Ministry of Education, the university possesses infrastructure, including a GMP production facility (total project grant of KRW 22 billion), capable of integrated support for the commercialization of technology for regional biotech companies. This project support is expected to strengthen the university's social role and contribute continuously to the development of key national industries.
• (Leveraging the host university's established R&D infrastructure and experience in corporate support projects)
By leveraging the 4D CONVERGENCE TECHNOLOGY INSTITUTE's (Korea National University of Transportation) established and operating R&D infrastructure at its biocampus and its successful experience and network in operating national technology development and commercialization projects for many years, the university aims to support and foster systematic technological collaboration. Furthermore, by establishing a value chain that connects university-based biotech research achievements to commercialization, the university aims to drive increased corporate sales and create quality jobs.